RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: R8-2B
Target: Cryptosporidium parvum (C.parvum) oocysts
Type of nucleic acid: ssDNA
Sequence: 5′CTCCTCTGACTGTAACCACGACAGGAGTAGGCGTTAACATAGGGCCGTGTCGGTTGTCAGGCATAGGTAGTCCAGAAGCC3′
Sequence length: 80
GC content: 0.55
Affinity: Not reported
Pool type: 5′-CTCCTCTGACTGTAACCACG-N40-GCATAGGTAGTCCAGAAGCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate buffered saline with CaCl2 and MgCl2 (DPBS)
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The main objectives of the present study were to obtain DNA aptamers binding to the oocyst wall of C. parvum, and to use the aptamers to detect the presence of this parasite in foods. DNA aptamers were selected against C. parvum oocysts using SELEX (Systematic Evolution of Ligands by EXponential enrichment). The high sensitivity and specificity of the developed aptasensor suggests that this novel method is very promising for the detection and identification of C. parvum oocysts on spiked fresh fruits, as compared to conventional methods such as microscopy and PCR."
Reference (2015, PLoS One ): Iqbal, A., Labib, M., Muharemagic, D., Sattar, S., Dixon, B. R., & Berezovski, M. V. (2015). Detection of Cryptosporidium parvum Oocysts on Fresh Produce Using DNA Aptamers. PloS one, 10(9), e0137455. https://doi.org/10.1371/journal.pone.0137455
Aptamer: R8-5
Target: Cryptosporidium parvum (C.parvum) oocysts
Type of nucleic acid: ssDNA
Sequence: 5′CTCCTCTGACTGTAACCACGCCCCAGTGACGGGTAGCAGAGCGTCCACAGTTTTCCTGTATGCATAGGTAGTCCAGAAGCC3′
Sequence length: 81
GC content: 0.5555555555555556
Affinity: Not reported
Pool type: 5′-CTCCTCTGACTGTAACCACG-N40-GCATAGGTAGTCCAGAAGCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate buffered saline with CaCl2 and MgCl2 (DPBS)
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The main objectives of the present study were to obtain DNA aptamers binding to the oocyst wall of C. parvum, and to use the aptamers to detect the presence of this parasite in foods. DNA aptamers were selected against C. parvum oocysts using SELEX (Systematic Evolution of Ligands by EXponential enrichment). The high sensitivity and specificity of the developed aptasensor suggests that this novel method is very promising for the detection and identification of C. parvum oocysts on spiked fresh fruits, as compared to conventional methods such as microscopy and PCR."
Reference (2015, PLoS One ): Iqbal, A., Labib, M., Muharemagic, D., Sattar, S., Dixon, B. R., & Berezovski, M. V. (2015). Detection of Cryptosporidium parvum Oocysts on Fresh Produce Using DNA Aptamers. PloS one, 10(9), e0137455. https://doi.org/10.1371/journal.pone.0137455
Aptamer: R8-6
Target: Cryptosporidium parvum (C.parvum) oocysts
Type of nucleic acid: ssDNA
Sequence: 5′CTCCTCTGACTGTAACCACGCCCCAGAGGGATCGGTAGGTGGGACTGTAGCGTTGGACCGGCATAGGTAGTCCAGAAGCC3′
Sequence length: 80
GC content: 0.6
Affinity: Not reported
Pool type: 5′-CTCCTCTGACTGTAACCACG-N40-GCATAGGTAGTCCAGAAGCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate buffered saline with CaCl2 and MgCl2 (DPBS)
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The main objectives of the present study were to obtain DNA aptamers binding to the oocyst wall of C. parvum, and to use the aptamers to detect the presence of this parasite in foods. DNA aptamers were selected against C. parvum oocysts using SELEX (Systematic Evolution of Ligands by EXponential enrichment). The high sensitivity and specificity of the developed aptasensor suggests that this novel method is very promising for the detection and identification of C. parvum oocysts on spiked fresh fruits, as compared to conventional methods such as microscopy and PCR."
Reference (2015, PLoS One ): Iqbal, A., Labib, M., Muharemagic, D., Sattar, S., Dixon, B. R., & Berezovski, M. V. (2015). Detection of Cryptosporidium parvum Oocysts on Fresh Produce Using DNA Aptamers. PloS one, 10(9), e0137455. https://doi.org/10.1371/journal.pone.0137455
Aptamer: FA3
Target: Human immunodeficiency virus reverse transcriptase (HIV-1 RT)
Type of nucleic acid: FANA XNA
Sequence: 5'AAAAGGTAGTGCTGAATTCGCAGGCCGGTAAGTATCCAAGGGATCCGGTTATTTCCTCCCTTCGCTATCCAGTTGGCCT3'
Sequence length: 79
GC content: 0.5063291139240507
Affinity: Kd: 0.270 ± 0.020 nM
Pool type: 5′-AGGCCAACTGGATAGCGAA-N40-CGAATTCAGCACTACCTTTTGGCAAACGCTAATAAGGG-3′
Pool random region: 40
Binding buffer/conditions: 50 mM Tris–HCl (pH 8), 80 mM KCl, 2 mM MgCl2 and 1 mM DTT
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Using a Systematic Evolution of Ligands by Exponential Enrichment (SELEX) protocol capable of selecting xeno-nucleic acid (XNA) aptamers, a 2'-deoxy-2'-fluoroarabinonucleotide (FANA) aptamer (referred to as FA1) to HIV-1 reverse transcriptase (HIV-1 RT) was selected. FA1 showed strong inhibition of HIV-1 RT in extension assays while no specific binding to avian myeloblastosis or Moloney murine leukemia RTs was detected. A complete DNA version of FA1 showed low binding to HIV-1 RT, emphasizing the unique properties of FANA in HIV-1 RT binding."
Additional information: Note that FANA is structurally distinct from the 2′-fluororibonucleotides described above as the sugar ring in FANA typically adopts a C2'/O4'-endo conformation as opposed to a C3'-endo conformation for 2′-fluoro-ribonucleotides, and the fluorine group in FANA is in the β as opposed to α conformation
Reference (2015, Nucleic Acids Res ): Alves Ferreira-Bravo, I., Cozens, C., Holliger, P., & DeStefano, J. J. (2015). Selection of 2'-deoxy-2'-fluoroarabinonucleotide (FANA) aptamers that bind HIV-1 reverse transcriptase with picomolar affinity. Nucleic acids research, 43(20), 9587–9599. https://doi.org/10.1093/nar/gkv1057
Aptamer: CD40Apt1
Target: CD40 receptor
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGAGACGAUGCGGCCAACGAGUAGGCGAUAGCGCGUGGCAGAGCGUCGCUGAGGAUCCGAGA3'
Sequence length: 65
GC content: 0.6461538461538462
Affinity: Kd: 20 nM
Pool type: 5'-CCTCAGCGACGCTCTG-N25-CCGCATCGTCTCTCCC-3'
Pool random region: 25
Binding buffer/conditions: 10 mM Tris-ClH, 100 mM NaCl and 10 mM EDTA
Buffer type: Tris Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " It is shown that CD40 agonist aptamers can be used to promote bone-marrow aplasia recovery. CD40 antagonist aptamers are revealed to have a direct antitumor effect on CD40-expressing B-cell lymphoma in vitro and in vivo. Further, in order to identify a therapeutic reagent that will generate the optimal conditions for cancer immunotherapy (antigen-presenting cell activation, tumor antigenicity enhancement and bone-marrow aplasia recovery), CD40 agonist aptamer-shRNA chimera was generated to target the inhibition of the Nonsense mRNA Mediated Decay (NMD) to tumor cells."
Additional information: We started with a randomized DNA library of 25 nucleotides flanked by two constant regions at the 5′ end and 3′ end, which were used to amplify the selected sequences in each round as well as to transcribe the DNA library into RNA by adding a T7-promoter and using a MutT7-polymerase to incorporate 2′F-pyrimidines in the RNA backbone to enhance RNAse resistance. 

Aptamer dimers were generated by adding a 21- nucleotide complementary sequence in the 3′ end of the aptamer and annealing each pair
Reference (2015, Biomaterials ): Soldevilla, M. M., Villanueva, H., Bendandi, M., Inoges, S., López-Díaz de Cerio, A., & Pastor, F. (2015). 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials, 67, 274–285. https://doi.org/10.1016/j.biomaterials.2015.07.020
Aptamer: CD40Apt1-dimer (CD40 agonist aptamer)
Target: CD40 receptor
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGAGACGAUGCGGCCAACGAGUAGGCGAUAGCGCGUGGCAGAGCGUCGCUGAGGAUCCGAGAGUUCUCAUGCACACUUAUAGCGGGAGAGACGAUGCGGCCAACGAGUCAGGCGAUACCGCGUGGCAGAGCGUCGCUGAGGAUCCGAGAGCUAUAAGUGUGCAUGAGAAC3'
Sequence length: 177
GC content: 0.5819209039548022
Affinity: Not reported
Pool type: 5'-CCTCAGCGACGCTCTG-N25-CCGCATCGTCTCTCCC-3'
Pool random region: 25
Binding buffer/conditions: 10 mM Tris-ClH, 100 mM NaCl and 10 mM EDTA
Buffer type: Tris Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " It is shown that CD40 agonist aptamers can be used to promote bone-marrow aplasia recovery. CD40 antagonist aptamers are revealed to have a direct antitumor effect on CD40-expressing B-cell lymphoma in vitro and in vivo. Further, in order to identify a therapeutic reagent that will generate the optimal conditions for cancer immunotherapy (antigen-presenting cell activation, tumor antigenicity enhancement and bone-marrow aplasia recovery), CD40 agonist aptamer-shRNA chimera was generated to target the inhibition of the Nonsense mRNA Mediated Decay (NMD) to tumor cells."
Additional information: We started with a randomized DNA library of 25 nucleotides flanked by two constant regions at the 5′ end and 3′ end, which were used to amplify the selected sequences in each round as well as to transcribe the DNA library into RNA by adding a T7-promoter and using a MutT7-polymerase to incorporate 2′F-pyrimidines in the RNA backbone to enhance RNAse resistance. 

Aptamer dimers were generated by adding a 21- nucleotide complementary sequence in the 3′ end of the aptamer and annealing each pair
Reference (2015, Biomaterials ): Soldevilla, M. M., Villanueva, H., Bendandi, M., Inoges, S., López-Díaz de Cerio, A., & Pastor, F. (2015). 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials, 67, 274–285. https://doi.org/10.1016/j.biomaterials.2015.07.020
Aptamer: CD40Apt3-dimer (CD40-blockade aptamer)
Target: CD40 receptor
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGAGACGAUGCGGGAUUAGUGGGUGGGUUGCCCCUCCGCAGAGCGUCGCUGAGGAUCCGAGAGUUCUCAUGCACACUUAUAGCGGGAGAGACGAUGCGGGAUUAGUGGGUGGGUUGCCCCUCCGCAGAGCGUCGCUGAGGAUCCGAGAGCUAUAAGUGUCAUGAGAAC3'
Sequence length: 175
GC content: 0.5771428571428572
Affinity: Not reported
Pool type: 5'-CCTCAGCGACGCTCTG-N25-CCGCATCGTCTCTCCC-3'
Pool random region: 25
Binding buffer/conditions: 10 mM Tris-ClH, 100 mM NaCl and 10 mM EDTA
Buffer type: Tris Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " It is shown that CD40 agonist aptamers can be used to promote bone-marrow aplasia recovery. CD40 antagonist aptamers are revealed to have a direct antitumor effect on CD40-expressing B-cell lymphoma in vitro and in vivo. Further, in order to identify a therapeutic reagent that will generate the optimal conditions for cancer immunotherapy (antigen-presenting cell activation, tumor antigenicity enhancement and bone-marrow aplasia recovery), CD40 agonist aptamer-shRNA chimera was generated to target the inhibition of the Nonsense mRNA Mediated Decay (NMD) to tumor cells."
Additional information: We started with a randomized DNA library of 25 nucleotides flanked by two constant regions at the 5′ end and 3′ end, which were used to amplify the selected sequences in each round as well as to transcribe the DNA library into RNA by adding a T7-promoter and using a MutT7-polymerase to incorporate 2′F-pyrimidines in the RNA backbone to enhance RNAse resistance. 

Aptamer dimers were generated by adding a 21- nucleotide complementary sequence in the 3′ end of the aptamer and annealing each pair
Reference (2015, Biomaterials ): Soldevilla, M. M., Villanueva, H., Bendandi, M., Inoges, S., López-Díaz de Cerio, A., & Pastor, F. (2015). 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials, 67, 274–285. https://doi.org/10.1016/j.biomaterials.2015.07.020
Aptamer: CD40Apt1 (CD40 agonist aptamer-shRNA chimera to target the inhibition of nonsense-mediated mRNA decay)
Target: CD40 receptor
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGGAAUUCUAAUACGACUCACUAUAGGGAGAGACGAUGCGGCCAACGAGUAGGCGAUAGCGCGUGGCAGAGCGUCGCUGAGGAUCCGAGAGGGAGAGACGAUGCGGCCAACGAGUAGGCGAUAGCGCGUGGCAGAGCGUCGCUGAGGAUCCGAGAUCUCGGAUCCUCAGCGACGCUCUGCCACGCGCUAUCGCCUACUCGUUGGCCGCAUCGUCUCUCCCUCUCGGAUCCUCAGCGACGCUCUGCCACGCGCUAUCGCCUACUCGUUGGCCGCAUCGUCUCUCCCUAUAGUGAGUCGUAUUAGAAUUCCCC3'
Sequence length: 312
GC content: 0.6025641025641025
Affinity: Not reported
Pool type: 5'-CCTCAGCGACGCTCTG-N25-CCGCATCGTCTCTCCC-3'
Pool random region: 25
Binding buffer/conditions: 10 mM Tris-ClH, 100 mM NaCl and 10 mM EDTA
Buffer type: Tris Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " It is shown that CD40 agonist aptamers can be used to promote bone-marrow aplasia recovery. CD40 antagonist aptamers are revealed to have a direct antitumor effect on CD40-expressing B-cell lymphoma in vitro and in vivo. Further, in order to identify a therapeutic reagent that will generate the optimal conditions for cancer immunotherapy (antigen-presenting cell activation, tumor antigenicity enhancement and bone-marrow aplasia recovery), CD40 agonist aptamer-shRNA chimera was generated to target the inhibition of the Nonsense mRNA Mediated Decay (NMD) to tumor cells."
Additional information: For the construction of the aptamer-shRNA chimeras, we used two DNA oligos with complementary sequences to generate a CD40Apt1 dimer.

We started with a randomized DNA library of 25 nucleotides flanked by two constant regions at the 5′ end and 3′ end, which were used to amplify the selected sequences in each round as well as to transcribe the DNA library into RNA by adding a T7-promoter and using a MutT7-polymerase to incorporate 2′F-pyrimidines in the RNA backbone to enhance RNAse resistance.
Reference (2015, Biomaterials ): Soldevilla, M. M., Villanueva, H., Bendandi, M., Inoges, S., López-Díaz de Cerio, A., & Pastor, F. (2015). 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials, 67, 274–285. https://doi.org/10.1016/j.biomaterials.2015.07.020
Aptamer: A3
Target: Epididymis 4, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGCACAGAGGTCAGATGCACAGTGCGTCACATTTAGGGCATTCCTATGCGTGCTACCGTGAA3'
Sequence length: 65
GC content: 0.5230769230769231
Affinity: Kd: 500 nM
Pool type: 5′AGCAGCACAGAGGTCAGATG-N25-CCTATGCGTGCTACCGTGAA-3′
Pool random region: 25
Binding buffer/conditions: 10 mM Tris, 2 mM NaCl, 1 mM EDTA at pH 7.6, 2× concentration
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Research and Detection: " The development of novel affinity probes for cancer biomarkers may enable powerful improvements in analytical methods for detecting and treating cancer. In this report, we describe our use of capillary electrophoresis (CE) as the separation mechanism in the process of selecting DNA aptamers with affinity for the ovarian cancer biomarker HE4. Bioinformatics tools are used to identify enrichment of selected aptamers and groupings into clusters based on sequence and structural similarity. A subset of sequenced aptamers may be intelligently chosen for in vitro testing."
Reference (2015, Anal Bioanal Chem ): Eaton, R. M., Shallcross, J. A., Mael, L. E., Mears, K. S., Minkoff, L., Scoville, D. J., & Whelan, R. J. (2015). Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing. Analytical and bioanalytical chemistry, 407(23), 6965–6973. https://doi.org/10.1007/s00216-015-8665-7
Aptamer: A9
Target: H9N2 avian influenza virus (AIV) purified haemagglutinin (HA)
Type of nucleic acid: ssDNA
Sequence: 5'GCTGCAATACTCATGGACAGCCTCCTGGGGTCAGGCTCAGACATTGATAAAGCGACATCGGTCTGGAGTACGACCCTGAA3'
Sequence length: 80
GC content: 0.5375
Affinity: Kd: 46.23 ± 5.46 nM
Pool type: 5'-GCTGCAATACTCATGGACAG-N40-GTCTGGAGTACGACCCTGAA-3'
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " New antiviral therapy for pandemic influenza mediated by the H9N2 avian influenza virus (AIV) is increasingly in demand not only for the poultry industry but also for public health. We studied two DNA aptamers, A9 and B4, selected by capillary electrophoresis-based systemic evolution of ligands by exponential enrichment (CE-SELEX) procedure using H9N2 AIV purified haemagglutinin (HA) as target. Our data provide a foundation for future development of innovative anti-influenza drugs."
Reference (2015, PLoS One ): Zhang, Y., Yu, Z., Jiang, F., Fu, P., Shen, J., Wu, W., & Li, J. (2015). Two DNA aptamers against avian influenza H9N2 virus prevent viral infection in cells. PloS one, 10(3), e0123060. https://doi.org/10.1371/journal.pone.0123060
Aptamer: B4
Target: H9N2 avian influenza virus (AIV) purified haemagglutinin (HA)
Type of nucleic acid: ssDNA
Sequence: 5'GCTGCAATACTCATGGACAGGGGCCGCGCCTGGTCGGTTGGGTGGGTGGCGCCCGGGACGGTCTGGAGTACGACCCTGAA3'
Sequence length: 80
GC content: 0.675
Affinity: Kd: 7.38 ± 1.09 nM
Pool type: 5'-GCTGCAATACTCATGGACAG-N40-GTCTGGAGTACGACCCTGAA-3'
Pool random region: 40
Binding buffer/conditions: Not reported
Buffer type: Not Reported
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " New antiviral therapy for pandemic influenza mediated by the H9N2 avian influenza virus (AIV) is increasingly in demand not only for the poultry industry but also for public health. We studied two DNA aptamers, A9 and B4, selected by capillary electrophoresis-based systemic evolution of ligands by exponential enrichment (CE-SELEX) procedure using H9N2 AIV purified haemagglutinin (HA) as target. Our data provide a foundation for future development of innovative anti-influenza drugs."
Reference (2015, PLoS One ): Zhang, Y., Yu, Z., Jiang, F., Fu, P., Shen, J., Wu, W., & Li, J. (2015). Two DNA aptamers against avian influenza H9N2 virus prevent viral infection in cells. PloS one, 10(3), e0123060. https://doi.org/10.1371/journal.pone.0123060
Aptamer: G-3
Target: C-C chemokine receptor type 5 (CCR5
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGGACGAUGCGGGCCUUCGUUUGUUUCGUCCACAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.6274509803921569
Affinity: Kd: ~110 nM
Pool type: 5′-GGGAGGACGATGCGG-N20-CAGACGACTCGCCCGA-3′
Pool random region: 20
Binding buffer/conditions: DPBS (pH 7.0 ~7.4) and Ca2+ and Mg2+, 1 mM CaCl2, 2.7 mM KCl, 1.47 mM KH2PO4, 1 mM MgCl2, 136.9 mM NaCl, 2.13 mM Na2HPO4 and yeast tRNA
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7
Molecular weight of target: Not reported
Post-SELEX modifications: Not appilcable
Application as quoted in the referenced paper: Therapeuitc: " The C-C chemokine receptor type 5 (CCR5) is a receptor expressed by T cells and macrophages that serves as a coreceptor for macrophage-tropic HIV-1. Here, we combine the live-cell-based SELEX with high-throughput sequencing technology to generate CCR5 RNA aptamers capable of specifically targeting HIV-1 susceptible cells (as small interfering RNA [siRNA] delivery agent) and inhibiting HIV-1 infectivity (as antiviral agent) via block of the CCR5 required for HIV-1 to enter cells. CCR5-targeted aptamers and aptamer-siRNA conjugates offer promise for overcoming some of the current challenges of drug resistance in HIV-1 by providing cell-type- or tissue-specific delivery of various therapeutic moieties."
Additional information:  In the transcription reaction mixture, CTP and UTP were replaced with 2′-F-CTP and 2′-F-UTP to produce ribonuclease-resistant RNA.
Reference (2015, Chem Biol ): Zhou, J., Satheesan, S., Li, H., Weinberg, M. S., Morris, K. V., Burnett, J. C., & Rossi, J. J. (2015). Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chemistry & biology, 22(3), 379–390. https://doi.org/10.1016/j.chembiol.2015.01.005
Aptamer: AO-01
Target: Matrix binding domain [MBD] Hepatitis B capsid
Type of nucleic acid: ssDNA
Sequence: 5' GCGGGTCGACGTTTGCACACGCGAGCCGCCATGTCTGGGCCACATCCATGGGCGG3'
Sequence length: 55
GC content: 0.6909090909090909
Affinity: Kd: 180 ± 82 nM
Pool type: 5′GCGGGTCGACGTTTG-N25-CACATCCATGGGCGG3′
Pool random region: 25
Binding buffer/conditions: Phosphate-buffered saline [PBS]
Buffer type: PBS/phosphate buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The hepatitis B virus (HBV) particle is an icosahedral nucleocapsid surrounded by a lipid envelope containing viral surface proteins. We selected a 55-base-long single-stranded DNA molecule (aptamer) which binds with relatively high affinity to a region on the HBV capsid interacting with viral envelope proteins during budding. This aptamer inhibits virion formation in cell culture. The results substantiate the current model for HBV morphogenesis and show that the capsid envelope interaction is a potential antiviral target."
Reference (2015, J Virol ): Orabi, A., Bieringer, M., Geerlof, A., & Bruss, V. (2015). An Aptamer against the Matrix Binding Domain on the Hepatitis B Virus Capsid Impairs Virion Formation. Journal of virology, 89(18), 9281–9287. https://doi.org/10.1128/JVI.00466-15
Aptamer: Bap5
Target: Brevetoxin-2 (BTX-2)
Type of nucleic acid: ssDNA
Sequence: 5′GAGGCAGCACTTCACACGATCTGTGAAGTTTTTGTCATGGTTTGGGGGTGGTAGGGGTGTTGTCTGCGTAATGACTGTAGTGATG3'
Sequence length: 85
GC content: 0.4941176470588235
Affinity: Kd: 4830 nM
Pool type: 5′-GAGGCAGCACTTCACACGATCTG-N40-CTGCGTAATGACTGTAGTGATG-3
Pool random region: 40
Binding buffer/conditions: 20 mM Hepes, 120 mM sodium chloride, 5 mM potassium chloride, 1 mM calcium chloride, and 1 mM magnesium chloride
Buffer type: Other Buffers
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The development of an alternative detection probe is another promising research direction. This paper reports the use of aptamers binding to BTX-2 in an analytical assay using the systematic evolution of ligands by exponential enrichment (SELEX). Moreover, there is no cross-reaction with the detected marine toxins, except for BTX-2. Thus, Bap5 has potential to detect BTX-2 in shellfish in the future as a substitute for the recognition probe."
Reference (2016, J Anal Methods Chem ): Tian, R. Y., Lin, C., Yu, S. Y., Gong, S., Hu, P., Li, Y. S., Wu, Z. C., Gao, Y., Zhou, Y., Liu, Z. S., Ren, H. L., & Lu, S. Y. (2016). Preparation of a Specific ssDNA Aptamer for Brevetoxin-2 Using SELEX. Journal of analytical methods in chemistry, 2016, 9241860. https://doi.org/10.1155/2016/9241860